42971-27-7

Basic information

• Product Name: 2-(1,3-benzodioxol-5-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide
• CAS NO: 42971-27-7
• Molecular Formula: C₁₉H₂₁NO₅
• Molecular Weight: 343.3737
• Mol File: 42971-27-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 564.3°C at 760 mmHg
• Flash Point: 295.1°C
• Density: 1.221g/cm³
• Vapor Pressure: 9.33E-13mmHg at 25°C
• Refractive Index: 1.573
• CAS DataBase Reference: 2-(1,3-benzodioxol-5-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1,3-benzodioxol-5-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide(42971-27-7)
• EPA Substance Registry System: 2-(1,3-benzodioxol-5-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide(42971-27-7)

Safety Data

• Hazardous Substances Data: 42971-27-7(Hazardous Substances Data)

Usage

Type of compound

substituted phenethylamine

Structural relation

related to the psychedelic drug mescaline

Psychoactive properties

known for its hallucinogenic effects

Recreational use

used for its mind-altering properties

Receptor interaction

potent agonist for the serotonin 5-HT2A receptor

Legal status

classified as a controlled substance in many countries

Adverse effects

can cause hallucinations, increased heart rate, and agitation

Potential for misuse

has potential for misuse and associated risks

Upstream product

• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 2861-28-1 1,3-benzodioxole-5-acetic acid 
• 2107-70-2 3,4-methoxycinnamic acid 
• 14773-41-2 3-(3,4-dimethoxyphenyl)propionic acid amide 

Downstream Products

• 1194765-46-2 2-(benzo[d][1,3]dioxol-5-yl)-N-(3,4-dimethoxyphenethyl)ethan-1-amine 
• 5884-67-3 armepavine 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

Identification of tris-(phenylalkyl)amines as new selective h5-HT2B receptor antagonists

A series of tris-(phenylalkyl)amines was synthesized and evaluated for affinity to human 5-HT2 receptors. In general, the compounds displayed high affinity (4 of 11 analogs had Ki values 2B receptor vs. other 5-HT2 receptors. Functional assays revealed that the compounds are 5-HT2B antagonists. This journal is

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.